trial · primary record
Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab
Advanced HER2-positive Breast Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 140 |
| Primary completion | 2031-03-31 |
| Primary endpoint | Objective response rate （ORR） |
| Registry ID | NCT07581795 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:32.949Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07581795
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.